References
- Curran M P, Wagstaff A J. Ethinylestradiol/Chlormadinone acetate. Drugs 2004; 64: 751–760
- Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63: 463–492
- Worret I, Arp W, Zahradnik H P, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®). Dermatology 2001; 203: 38–44
- Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®): results of a postmarketing surveillance study. Clin Drug Invest 2002; 22: 221–231
- Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305–312
- Zahradnik H P, Goldberg J, Andreas J O. Efficacy and safety of the new anti-androgenic oral contraceptive Belara®. Contraception 1998; 57: 103–109
- Bitzer J. Contraception from the women's point of view (Part 1). Praxis 2000; 89: 1142–1146
- Bitzer J. Contraception from the women's point of view (Part 2): Longterm pill users are convinced of the advantages of hormonal contraception. Praxis 2000; 89: 1237–1242
- Bitzer J, Hänggi W, Husslein P, et al. Longterm contraception. Recommendations of an Austrian-Swiss-Working Group. Gynäkologisch-geburtshilfliche Rundschau 2002; 41: 253–259